Moteur de recherche d’entreprises européennes
Financement de l’UE (1 058 000 €) : Biologie structurale intégrative de la protéine tau pathologique, une cible thérapeutique intéressante pour les médicaments modificateurs de la maladie d’Alzheimer Hor 09/12/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Biologie structurale intégrative de la protéine tau pathologique, une cible thérapeutique intéressante pour les médicaments modificateurs de la maladie d’Alzheimer
There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease- modifying therapies for neurodegenerative disorders, including Alzheimer’s disease (AD), other tauopathies and Parkinson’s disease (PD). The common molecular denominator of tauopathies are pathological forms of tau protein, and in Parkinson’s disease these are pathological forms of -synuclein. Moreover, -synuclein has a distinct role in pathophysiology of tauopathies, mainly in tau hyperphosphorylation and aggregation, and vice versa. Tau pathology relates to conformational changes during oligomerization and assembly resulting in toxicity. Given their role in the pathogenesis, conformationally altered and assembled tau or -synuclein would be a promising molecular target for disease-modifying therapies. However, the field is still lacking a deeper understanding of associated structural changes in the course of assembly and their inducers on the pathway towards pathological forms of these proteins; therefore, the pharma development is hampered. The main aim of the InterTau project is the detailed structural and biophysical characterization of tau and -synuclein -synuclein protein and their variants in monomeric, oligomeric and fibrillar states relevant for AD, other tauopathies. The InterTAU consortium is composed and academic partners with cutting- edge methodologies suitable for functional and structural characterization of the tau assembly pathway by solution and solid-state nuclear magnetic resonance (NMR), cryo-electron microscopy and cellular assays corroborated by bioinformatics. The mutual transfer of complementary expertise envisaged in the project will facilitate academic outcome and biotechnological development. Specific expertise will be transferred from three institutions in North America and one institution from Argentina. The results of InterTAU will be directly translated into innovation in biotech through the non-academic partner. The platform for sharing knowledge will be a foundation of sustainable cooperation beyond the InterTau project.
| Oregon State University | ? |
| Axon Neuroscience R&D Services SE | 11 500,00 € |
| Biovendor Laboratorni Medicina s.r.o. | 0,00 € |
| Datamedrix GmbH | 13 800,00 € |
| Geneton s.r.o. | 0,00 € |
| Latvijas Organiskas Sintezes Instituts | 82 800 € |
| Masarykova Univerzita | 407 100 € |
| Neuroimunologicky Ustav Slovenskej Akademie Vied, v. v. i. | 492 200 € |
| Omiics ApS | 0,00 € |
| Royal College of Surgeons in Ireland | 50 600 € |
https://cordis.europa.eu/project/id/873127
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Oregon State University SCHOOL, Corvallis, États-Unis.
